Xgeva is manufactured in the United States and shipped by courier from our pharmacy in India.
Information about Xgeva (Denosumab)
Xgeva is a medication used to prevent skeletal-related events (such as fractures) in patients with bone metastases from solid tumors and to treat conditions related to bone loss, such as osteoporosis in certain populations. It works by inhibiting RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a protein that plays a crucial role in the formation, function, and survival of osteoclasts (cells that break down bone tissue). By blocking RANKL, Xgeva helps prevent bone loss and reduces the risk of complications associated with bone metastases.
Product Highlights
- Xgeva is used to prevent skeletal-related events in patients with bone metastases from solid tumors (such as breast, prostate, and lung cancer).
- Xgeva is approved for the treatment of giant cell tumor of bone, a rare but aggressive tumor that can cause bone damage.
- Xgeva is also used in certain patients undergoing hormone therapy for cancer (such as prostate or breast cancer) to prevent bone loss.
- In some cases, Xgeva is used to treat osteoporosis in postmenopausal women or men at high risk for fractures.
Key Ingredient
Key Benefits
- Xgeva reduces the risk of fractures and other skeletal-related events in cancer patients with bone metastases.
- It can slow or prevent bone complications caused by metastatic cancer cells, which can weaken bones.
- By inhibiting bone resorption, Xgeva helps increase bone density, reducing the risk of fractures in patients with osteoporosis or other bone loss conditions.
- Xgeva is typically given as a subcutaneous injection every 4 weeks, making it a convenient treatment option for long-term management.
Direction of Use
- Xgeva is usually administered as a subcutaneous injection by a healthcare professional once every 4 weeks.
- The injection is typically given into the thigh, abdomen, or upper arm. It should be administered by a healthcare provider who is experienced in giving subcutaneous injections.
- Calcium levels should be monitored, as denosumab may cause low calcium levels in some individuals. Supplementation may be required.
Safety Concerns
- Xgeva can cause low calcium levels, especially in individuals who are already prone to this condition. Calcium and vitamin D levels should be monitored and corrected before starting treatment.
- There is a risk of osteonecrosis (death of jawbone tissue) with Xgeva, particularly in cancer patients undergoing dental procedures or who have poor oral hygiene.
- Xgeva may increase the risk of serious infections, including skin, urinary tract, and respiratory infections. Patients should be monitored for signs of infection.
- Although Xgeva is used to reduce bone fractures, there is a rare risk of atypical femur fractures, especially with long-term use.
- Renal monitoring is necessary in patients with pre-existing kidney issues, as denosumab can affect renal function in some individuals.
- Xgeva should not be used during pregnancy or while breastfeeding due to potential risks to the fetus or infant.
Avoid Xgeva (Denosumab) If
- If you have a known allergy to denosumab or any of the ingredients in Xgeva, you should not use it.
- If you have low calcium levels, Xgeva may worsen the condition. Ensure that calcium levels are corrected before starting treatment.
- Xgeva should not be used during pregnancy or breastfeeding unless clearly necessary. It can harm a fetus or infant.
- If you have severe renal impairment, your healthcare provider may recommend an alternative treatment, as Xgeva can affect kidney function.
- If you have an active infection or are immunocompromised, your healthcare provider may assess the risks and benefits before prescribing Xgeva.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
